A critical review of brand and generic alendronate for the treatment of osteoporosis
- Authors
- A Dobrucali
- A Lainesse
- A Papaioannou
- A Papaioannou
- A Parthan
- AA Reszka
- AC Perkins
- AD Anastasilakis
- AG Porras
- AM Gallagher
- B Ettinger
- B Jonsson
- C MacLean
- D Weycker
- DM Black
- DM Black
- DO Castell
- DR Bolanos
- DT Grima
- DY Graham
- E Landfeldt
- ES Siris
- ES Siris
- Federal Drug Administration
- Federal Drug Administration
- G Ioannidis
- G Lamprecht
- G Naylor
- H Halkin
- H Yun
- Health Canada
- HG Bone
- I Imaz
- J Blouin
- JD Ringe
- JE Tarride
- JF van Boven
- JP Devogelaer
- KE Hansen
- L Bessette
- L Giangregorio
- M Hiligsmann
- M Rossini
- M Shakweh
- MH Yun
- MR McClung
- USA National Institutes of Health
- O Sheehy
- O Sheehy
- O Strom
- O Strom
- P Meredith
- PC de Groen
- Prescribing information
- PS Lai
- Q Dai
- R Rizzoli
- RJ Dansereau
- RJ Dansereau
- RK Mittal
- RP Tonino
- Régie de l'assurance maladie du Québec
- S Almeida
- S Epstein
- S Epstein
- S Kane
- S Nayak
- SH Ralston
- SR Cummings
- ST Harris
- SV Dighe
- SY Rhim
- T Schnitzer
- UA Liberman
- V Rabenda
- W Drake
- W Strampel
- World Health Organization
- Publication date
- Publisher
- 'Springer Science and Business Media LLC'
- Doi